伊卡里在帕金森病中的治疗效果和机制
Chongbo Zheng1,2, Lizhen Wu1,3, Liang Luo1,2
1Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Ganzhou Key Laboratory of Neuroinflammation Research, Gannan Medical University, Ganzhou 341000, China.
Current pharmaceutical design
|February 14, 2025
概括
伊卡里 (ICT) 是一种植物性雌激素,通过减少氧化应激和炎症,有望保护大脑细胞免受帕金森病 (PD) 的影响. 本综述探讨了ICT作为PD预防和治疗的新型治疗策略的潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,影响中枢神经系统 (CNS).
- 目前针对PD的干预措施不足以阻止疾病的进展.
- 全球人口老龄化加剧了PD的公共卫生负担.
研究的目的:
- 审查Icaritin (ICT) 的神经保护作用,一种来自Epimedium Brevicornu Maxim.的黄类药物.
- 探索ICT对抗帕金森病的潜在机制.
- 为ICT在PD预防和治疗中的应用提供见解.
主要方法:
- 关于Icaritin (ICT) 及其对神经保护的影响的文献综述.
- 分析ICT对多巴胺基神经元的影响.
- 检查ICT对氧化应激,线粒体功能,神经炎症,莱维体形成和亡的影响.
主要成果:
- 伊卡里 (ICT) 具有显著的神经保护性.
- 通过抗氧化,抗炎和抗亡机制,ICT可以减轻PD病理.
- 信息通信技术改善了线粒体功能,并可能减少勒维体的形成.
结论:
- 伊卡里 (ICT) 在预防和治疗帕金森病方面显示出相当大的潜力.
- 它的多方面的神经保护作用需要进一步研究临床应用.
- 信息通信技术代表了神经退行性疾病 (如PD) 的有希望的治疗候选者.
相关概念视频
Parkinson's Disease: Treatment
187
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
187
Parkinson's Disease: Overview
429
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
429
Cholinergic Antagonists: Therapeutic Uses
703
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
703
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Heart Failure Drugs: Inotropic Agents
500
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
500
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


